<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0412246364
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Lotinil
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LOTEPREDNOL ETABONATE,TOBRAMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5,0.3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ophthalmic use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lotinil&trade; is an eye drop suspension.<br />Lotinil&trade; is indicated for steroid-responsive<br />inflammatory ocular conditions for which a<br />corticosteroid is indicated and where superficial<br />bacterial ocular infection or a risk of bacterial<br />ocular infection exists.<br />Corticosteroids inhibit the inflammatory response,<br />they inhibit the edema, fibrin deposition, capillary<br />dilation, leukocyte migration, capillary<br />proliferation, fibroblast proliferation, deposition of<br />collagen, and scar.<br />The antibiotic component in the combination<br />(tobramycin) is included to provide action against<br />susceptible organisms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Lotinil&trade;:<br />&bull; if you are allergic to the active substances<br />(loteprednol or tobramycin) or any of the other<br />ingredients of this medicine (listed in section 6).<br />&bull; if you have been allergic to any other<br />corticosteroid.<br />&bull; if you have eye diseases caused by viruses such<br />as herpes simplex, vaccinia, and varicella.<br />&bull; if you have eye diseases caused by<br />mycobacterium and fungi.<br />&bull; If you are breast-feeding.<br />Warnings and precautions<br />&bull; Tell your doctor if you already have glaucoma.<br />&bull; Contact your doctor if you experience blurred<br />vision or other visual disturbances.<br />&bull; Tell your doctor if pain develops, or if redness,<br />itching, or inflammation gets worse.<br />&bull; See your doctor if your symptoms do not get<br />better within 2 days. He/she may want to<br />re-evaluate your condition.<br />&bull; You should not use Lotinil&trade; longer than 10 days<br />without having the pressure in your eye checked<br />by your doctor.<br />&bull; Long-term use of Lotinil&trade; or other eye drops<br />that contain steroids, may result in glaucoma or<br />raised pressure in the eye, which can cause<br />damage to the optic nerve, problems with vision,<br />and cataracts.<br />&bull; Long-term use of Lotinil&trade; or other eye drops<br />that contain steroids, may lower your ability to<br />fight infections and may increase your chance of<br />getting an eye infection including herpes simplex.<br />&bull; Using steroid eye drops like Lotinil&trade; may make<br />viral diseases of the eye worse and last longer.<br />Contact lenses<br />As with all ophthalmic preparations containing<br />benzalkonium chloride, patients should be advised<br />not to wear soft contact lenses when using<br />Lotinil&trade;.<br />Other medicines and Lotinil&trade;<br />Please tell your doctor if you are taking or have<br />recently taken any other medicines, including<br />medicines obtained without a prescription.<br />Especially, tell you doctor if you use:<br />&bull; medicines known as anticholinergics (used to<br />treat a variety of conditions, e.g. gastrointestinal<br />cramps, muscular spasms, urge incontinence or<br />asthma)<br />&bull; eye drops for the treatment of high pressure in<br />the eye.<br />Some medicines may increase the effects of<br />Lotinil&trade; and your doctor may wish to<br />monitor you carefully if you are taking these<br />medicines (including some medicines for HIV:<br />ritonavir, cobicistat).<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you<br />may be pregnant or are planning to have a baby,<br />ask your doctor or pharmacist for advice before<br />taking this medicine.<br />It is possible that you may still receive Lotinil&trade;,<br />but it is also possible that an alternative may be<br />used.<br />Driving and using machines<br />Eye drops can cause your vision to be blurred.<br />This usually passes quickly. Do not drive or use<br />machines until your vision is clear.<br />Lotinil&trade; contains benzalkonium chloride<br />The preservative benzalkonium chloride may<br />cause eye irritation.<br />Avoid contact with soft contact lenses. Remove<br />contact lenses prior to application and wait at least<br />15 minutes before reinsertion. Benzalkonium<br />chloride is known to discolour soft contact lenses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or<br />pharmacist has told you. Check with your doctor<br />or pharmacist if you are not sure.<br />The recommended dose for adults and elderly is to<br />apply one or two drops of Lotinil&trade; into the<br />conjunctival sac of the affected eye every four to<br />six hours.<br />During the initial 24 to 48 hours, the dosing may<br />be increased, to every one to two hours. Frequency<br />should be decreased gradually as warranted by<br />improvement in clinical signs. Care should be<br />taken not to discontinue therapy prematurely.<br />Use in adults<br />&bull; Shake Lotinil&trade; well before using.<br />&bull; Look upwards and gently pull down the lower<br />eyelid of the affected eye(s).<br />&bull; Apply one to two drops of Lotinil&trade; into the<br />gap between your eyeball and eyelid.<br />&bull; Do not allow the tip of the dropper to touch any<br />surface because this may contaminate the<br />medicine.<br />&bull; The bottle should be closed immediately after<br />use.</p><p>&bull; Your doctor will tell you how long your<br />treatment with Lotinil&trade; will last.<br />&bull; Do not stop treatment without talking with your<br />doctor.<br />Use in children and adolescents<br />Lotinil&trade; should not be used in children and<br />adolescents until further data becomes available.<br />If you use more Lotinil&trade; than you should<br />Tell your doctor or a pharmacist.<br />If you forget to use Lotinil&trade;<br />Do not take a double dose to make up for a<br />forgotten dose. Wait until the next dose and then<br />continue as before.<br />If you stop using Lotinil&trade;<br />Always use this medicine exactly as your doctor<br />has told you. Do not stop using Lotinil&trade;<br />without speaking to your doctor first.<br />If you have any further questions on the use of this<br />medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side<br />effects, although not everybody gets them.<br />If you experience any of the following symptoms:<br />redness, itching or swelling of the membrane<br />covering the white part of the eye and/or eyelid(s)<br />or general symptoms such as difficulty breathing,<br />difficulty swallowing, flushing or redness of the<br />face and swelling of the face or tongue you should<br />stop using this medicine and seek immediate<br />medical advice. These could be the signs of severe<br />allergic reaction.<br />You may notice any of the following side effects:<br />&bull; Ocular reactions reported with an incidence less<br />than 4% include vision disorders, discharge,<br />itching, lacrimation disorder, photophobia, corneal<br />deposits, ocular discomfort, eyelid disorder, and<br />other unspecified eye disorders.<br />&bull; The incidence of non-ocular reactions reported in<br />approximately 14% of subjects was headache<br />&bull; All other non-ocular reactions had an incidence of<br />less than 5%.<br />&bull; Reactions associated with ophthalmic steroids<br />include elevated intraocular pressure, which may<br />be associated with infrequent optic nerve damage,<br />visual acuity and field defects, posterior<br />subcapsular cataract formation, delayed wound<br />healing and secondary ocular infection from<br />pathogens including herpes simplex, and<br />perforation of the globe where there is thinning of<br />the cornea or sclera.<br />&bull; The most frequent adverse reactions to topical<br />tobramycin are hypersensitivity and localized<br />ocular toxicity, including lid itching and swelling<br />and conjunctival erythema. These reactions occur<br />in less than 4% of patients. Similar reactions<br />may occur with the topical use of other<br />aminoglycoside antibiotics.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or<br />pharmacist. This includes any possible side effects<br />not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store the container in an upright position.<br />Do not store above 30 &deg;C.<br />Do not freeze.<br />Discard after 30 days of opening.<br />Do not use Lotinil&trade; after the expiry date which<br />is stated on the bottle and on the carton.<br />Medicines should not be disposed of via waste<br />water or household waste. Ask your pharmacist<br />how to dispose of medicines no longer required.<br />These measures will help to protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredients are:<br />Loteprednol Etabonate and Tobramycin<br />Each mL contains: Loteprednol Etabonate 5 mg<br />(0.5%) and Tobramycin 3 mg (0.3%)<br />Preservative : Benzalkonium chloride - 0.01%<br />&bull; The other ingredients are EDTA, Glycerol,<br />povidone, Tyloxapol, Sulfuric acid &amp; or<br />sodium hydroxide (for pH adjustment) and water<br />for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                • Lotinil™ Eye Drops is Off white suspension.
• Lotinil™ Eye Drops 5 mL filled in LDPE
bottles.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111. Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety<br />Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>طرة للعین ھي عبارة عن معلق یستخدم كقطرة للعین. &trade; لوتینیل<br />لعلاج حالات التھاب العین المستجیبة للستیروید &trade; تُستخدم لوتینیل<br />والتي یستخدم لھا الكورتیكوستیرویدات مع وجود عدوى بكتیریة<br />سطحیة للعین أو خطر الإصابة بعدوى بكتیریة في العین.<br />تقلل الكورتیكوستیرویدات الاستجابة للالتھابات ، فھي تمنع<br />الوذمة ، ترسب الفیبرین ، تمدد الشعیرات الدمویة ، انتقال الكریات<br />البیضاء ، انتشار الشعیرات الدمویة ، انتشار الخلایا اللیفیة ،<br />ترسب الكولاجین ، والندبة.<br />یتم تضمین مكون المضاد الحیوي في التركیبة (توبرامیسین)<br />لتوفیر فعالیة ضد الكائنات الحیة الحساسة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; إذا كنت تُعاني من حساسیة تجاه المواد الفعّالة (لوتیبریدنول أو<br />توبرامیسین) أو أيِّ مكوّن من المكونات الأخرى الداخلة في تركیب<br />.( ھذا الدواء (المُدرجة في القسم رقم ٦<br />&bull; إذا كنت تعاني من حساسیة تجاه الكورتیكوستیرویدات.<br />&bull; إذا كنت تعاني من أمراض في العین ناتجة عن فیروسات مثل<br />الھربس البسیط، الوَقْس (جدري البقر) والحماق النطاقي (جدري<br />الماء).<br />&bull; إذا كنت تعاني من أمراض في العین ناتجة عن المتفطّرات (أحد<br />أنواع الجراثیم) والفطریات.<br />&bull; إذا كنتِ تمارسین الرضاعة الطبیعیة.<br />تحذیرات واحتیاطات<br />&bull; أخبر الطبیب المعالج لك إذا كنت تعاني بالفعل من الجلوكوما<br />(المیاه الزرقاء داخل العین).<br />&bull; اتصل بالطبیب المعالج لك إذا شعرت بعدم وضوح الرؤیة أو<br />عانیت من أي اضطرابات بصریة أخرى.<br />&bull; أخبر الطبیب المعالج إذا أصبت بالألم أو إذا تفاقم الاحمرار أو<br />الحكة أو الالتھابات.<br />&bull; قم بزیارة الطبیب المعالج لك إذا لم تتحسن الأعراض خلال<br />یومین، فقد یرغب في إعادة تقییم حالتك.<br />قطرة للعین لأكثر من ۱۰ أیام دون &trade; &bull; یجب عدم استخدام لوتینیل<br />أن یفحص الطبیب المعالج لك ضغط العین.<br />قطرة للعین أو &trade; &bull; قد یؤدي الاستخدام طویل الأمد لدواء لوتینیل<br />قطرات العین الأخرى التي تحتوي على الستیرویدات إلى الإصابة<br />بالجلوكوما أو ارتفاع ضغط العین، مما قد یتسبب في تلف العصب<br />البصري وحدوث مشاكل في الرؤیة وإعتام عدسة العین.<br />قطرة للعین أو &trade; &bull; قد یقلل الاستخدام طویل الأمد لدواء لوتینیل<br />قطرات العین الأخرى التي تحتوي على الستیرویدات من قدرتك<br />على محاربة العدوى وقد یزید من فرص الإصابة بعدوى العین بما<br />في ذلك الھرْبس البسیط.<br />&bull; قد یؤدي استخدام القطرات التي تحتوي على مركب الستیروید<br />قطرة للعین إلى تفاقم الأمراض الفیروسیة &trade; العضوي مثل لوتینیل<br />التي تصاب بھا العین واستمرارھا لفترة أطول.<br />العدسات اللاصقة<br />كما ھو الحال مع جمیع مستحضرات العیون التي تحتوي على<br />كلورید البنزالكونیوم ، یجب نصح المرضى بعدم ارتداء العدسات<br />.&trade; اللاصقة اللینة عند استخدام لوتینیل<br />قطرة للعین مع الأدویة الأخرى &trade; استخدام لوتینیل<br />یُرجى إبلاغ الطبیب المعالج لك إذا كنت تتناول أو قد تناولت<br />مؤخرًا أیّة أدویة أخرى، بما في ذلك الأدویة التي حصلت علیھا<br />بدون وصفة طبیة. أخبر الطبیب المعالج لك؛ خاصةً إذا كنت تتناول<br />أي من الأدویة التالیة:<br />&bull; الأدویة المعروفة باسم مضادّات الكولین (التي تستخدم لعلاج<br />مجموعة من الحالات المختلفة، مثل تقلّصات الجھاز الھضمي،<br />التقلصات العضلیة، سلس البول أو الرّبو).<br />&bull; قطرات العین المستخدمة في علاج ارتفاع ضغط العین.<br />قطرة للعین وقد یرغب &trade; قد تُزید بعض الأدویة من تأثیر لوتینیل<br />الطبیب المعالج لك في مراقبة حالتك الصحیة بعنایة إذا كنت تتناول<br />ھذه الأدویة (بما في ذلك بعض الأدویة الخاصة بفیروس نقص<br />المناعة البشریة: ریتونافیر، كوبیسیستات).<br />الحَمْل والرضاعة الطبیعیة<br />إذا كُنتِ حاملًا أو تمارسین الرضاعة الطبیعیة، أو تعتقدین أنكِ<br />حاملاً أو تخططین لإنجاب طفل، فاستشیري الطبیب المعالج لكِ أو<br />الصیدلي قبل استخدام ھذا الدَّواء.<br />قطرة للعین ولكن من &trade; من المحتمل أن تواصلي استخدام لوتینیل<br />الممكن أیضًا استخدام دواء بدیل.<br />القیادة واستخدام الآلات<br />قد تسبب قطرة العین عدم وضوح الرؤیة الذي عادةً ما ینتھي<br />سریعًا. وبالتالي علیك تجنّب القیادة أو استخدام الآلات حتى تتضح<br />لك الرؤیة مرة أخرى.<br />قطرة للعین على كلورید البنزالكونیوم &trade; تحتوي لوتینیل<br />یمكن أن تسبب المادة الحافظة كلورید البنزالكونیوم في تھیّج<br />العینین.<br />قطرة للعین للعدسات اللاصقة اللینة. &trade; تجنب ملامسة لوتینیل<br />یجب إخبار المرضى بإزالة العدسات اللاصقة قبل الاستخدام و<br />الانتظار ۱٥ دقیقة على الأقل قبل إعادة وضعھا بالعین مرة أخرى.<br />حیث من المعروف أن كلورید البنزالكونیوم یُسبب تغیّر لون<br />العدسات اللاصقة اللینة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استخدم دائمًا ھذا الدَّواء تمامًا كما أخبرك طبیبك أو الصیدلي<br />الخاص بك. استشر طبیبك أو الصیدلي الخاص بك إذا لم تكن<br />متأكدًا من كیفیة الاستخدام.<br />الجرعة المُوصى بھا للمرضى من البالغین وكبار السن ھى وضع<br />في كیس الملتحمة للعین المصابة &trade; قطرة أو قطرتین من لوتینیل<br />كل أربع إلى ست ساعات.<br />خلال ال ۲٤ إلى ٤۸ ساعة الأولى ، یمكن زیادة الجرعات ، كل<br />ساعة إلى ساعتین. یجب تقلیل التكرار تدریجیًا حسب ما یقتضیھ<br />التحسن في العلامات السریریة. یجب الحرص على عدم التوقف<br />عن العلاج قبل الأوان.<br />الاستخدام في المرضى من البالغین<br />قطرة للعین جیدًا قبل الاستخدام. &trade; &bull; قم برجّ عبوة لوتینیل<br />&bull; انظر للأعلى ثمّ قمْ بلطف بسحب الجفن السفلي للعین (العینین)<br />المُصابة لأسفل.<br />قطرة للعین في &trade; &bull; ضع قطرة واحدة إلى قطرتین من لوتینیل<br />الفجوة بین مُقلة العین والجفن.<br />&bull; لا تدع طرف القطّارة یلمس أي سطح من العین لأن ذلك قد یسبّب<br />تلوّث الدواء.<br />&bull; یجب غلق الزجاجة فورًا بعد استخدامھا.<br />&bull; سیخبرك الطبیب المعالج لك بالمدة التي سیستمر فیھا علاجك<br />قطرة للعین. &trade; باستخدام لوتینیل<br />قطرة للعین بدون استشارة &trade; &bull; لا تتوقف عن استخدام لوتینیل<br />الطبیب المعالج لك أولًا.</p><p>الاستخدام في المرضى من الأطفال والمراھقین<br />قطرة للعین في المرضى من الأطفال &trade; یَحظر استخدام لوتینیل<br />والمراھقین حتى تتوفر بیانات إضافیة.<br />قطرة للعین: &trade; إذا استخدمت كمیة أكثر مما یجب من لوتینیل<br />قم بإبلاغ الطبیب المعالج لك أو الصیدلي الخاص بك.<br />قطرة للعین &trade; إذا أغفلت استخدام لوتینیل<br />لا تستخدم جرعة مضاعفة لتعویض جرعة أغفلتھا. وانتظر موعد<br />الجرعة التالیة ثم تابع الاستخدام كما كان من قبل.<br />قطرة للعین &trade; إذا توقفت عن استخدام لوتینیل<br />استخدم دائمًا ھذا الدواء تمامًا كما أخبرك الطبیب المعالج لك. ولا<br />قطرة للعین دون التحدُّث إلى الطبیب &trade; تتوقف عن استخدام لوتینیل<br />المعالج لك أولًا.<br />إذا كانت لدیك أیّة أسئلة إضافیة حول استخدام ھذا الدواء، فاستشر<br />الطبیب المعالج لك أو الصیدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یُسبب ھذا الدواء، مثلھ مثل كافة الأدویة، آثارًا جانبیة على الرغم<br />من عدم حدوثھا لجمیع المرضى.<br />إذا عانیت أیًا من الأعراض التالیة:<br />احمرار أو حكّة أو تورّم بالغشاء الذي یغطي الجزء الأبیض من<br />العین و/أو الجفون أو عند الشعور بأعراض عامة مثل صعوبة<br />التنفس أو صعوبة البلع أو احمرار الوجھ وتورم الوجھ أو اللسان؛<br />فیجب علیك حینئذٍ التوقف عن استخدام ھذا الدَّواء وطلب المشورة<br />الطبیة فورًا؛ فقد تكون ھذه علامات لحدوث تفاعلات تحسسیة<br />شدیدة.<br />قد تلاحظ أیًا من الآثار الجانبیة التالیة:<br />٪ &bull; ردود الفعل على العین التي تم الإبلاغ عنھا بنسبة أقل من ٤<br />تشمل اضطرابات الرؤیة ، الإفرازات ، الحكة ، اضطراب الدمع ،<br />رھاب الضوء ، رواسب القرنیة ، عدم الراحة في العین ، اضطراب<br />الجفن ، واضطرابات العین الأخرى غیر المحددة.<br />&bull; كان حدوث ردود الفعل غیر العینیة المبلغ عنھا في حوالي<br />۱٤ ٪ من الحالات عبارة عن صداع.<br />&bull; جمیع التفاعلات غیر العینیة الأخرى كان معدل حدوثھا أقل من<br />.٪٥<br />&bull; ردود الفعل المرتبطة بالستیرویدات العینیة تشمل ارتفاع ضغط<br />العین ، والتي قد تترافق نادرا مع تلف العصب البصري ، خلل في<br />حدة و مجال البصر، تشكل الساد الخلفي تحت المحفظة ، تأخر التئام<br />الجروح وعدوى العین الثانویة من مسببات الأمراض بما في ذلك<br />الھربس البسیط ، وانثقاب كرة العین حیث یوجد ترقق في القرنیة<br />أو الصلبة العینیة.<br />&bull; ردود الفعل السلبیة الأكثر شیوعًا للتوبرامیسین الموضعي ھي<br />فرط الحساسیة والسمیة العینیة الموضعیة ، بما في ذلك حكة الجفن<br />٪ و تورم واحمرار الملتحمة. تحدث ھذه التفاعلات في أقل من ٤<br />من المرضى. قد تحدث تفاعلات مماثلة مع الاستخدام الموضعي<br />لمضادات حیویة أمینوجلیكوزید أخرى.<br />الإبلاغ عن الآثار الجانبیة<br />إذا عانیت من أي من الآثار الجانبیة، فتحدَّث إلى الطبیب المعالج لك<br />أو الصیدلي الخاص بك. یشمل ذلك أیّة آثار جانبیة مُحتمَلة غیر<br />مُدرجة في ھذه النَّشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یُحفظ بعیداً عن متناول و مرأى الأطفال.<br />تُحفظ العبوة في وضع قائم ورأسي.<br />م. &ordm; یُحفظ في درجة حرارة لا تزید عن ۳۰<br />لا یجمد.<br />یتلف الدواء بعد ۳۰ یوماً من فتح الغطاء.<br />قطرة للعین بعد انتھاء تاریخ الصلاحیة &trade; &bull; لا تستخدم لوتینیل<br />المدون على الزجاجة وعلى العبوة الكرتونیة.<br />&bull; لا یتم التخلص من الأدویة عن طریق میاه الصرف أو<br />النفایات المنزلیة. إسأل الصیدلي عن طریقة التخلص من<br />الأدویة الغیر مرغوب فیھا فسوف تساعد ھذه الإجراءات على<br />حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>طرة للعین &trade; على ماذا تحتوي لوتینیل<br />&bull; المواد الفعاّلة ھي: لوتیبریدنول ایتابونات و توبرامیسین<br />كل ۱ مل یحتوي على: لوتیبریدنول ایتابونات ٥ ملغ ( ۰٫٥ ٪) و<br />(٪ توبرامیسین ۳ ملغ ( ۰,۳<br />٪ المادة الحافظة: كلورید البنزالكونیوم ۰٫۰۱<br />&bull; المكونات الأخرى ھي إدیتات، جلیسرول، بوفیدون، تیلوكسابول،<br />حمض الكبریتیك و / أو ھیدروكسید الصودیوم (لضبط درجة<br />الحموضة) و ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>قطرة للعین ھى معلق لونھ مائل للأبیض. &trade; &bull; لوتینیل<br />قطرة للعین، ٥ مل في قطارة مصنوعة من البولي &trade; &bull; لوتینیل<br />إیثیلین منخفض الكثافة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدویة،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- ھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />- المركز الوطني للتیقظ و السلامة الدوائیة<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفیذیة للتیقظ وإدارة الأزمات. o<br />+۹٦٦-۱۱- ھاتف: ۲۰۳۸۲۲۲ o<br />۲۳٤۰-۲۳٥٦- تحویلة: ۲۳۱۷<br />الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الالكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lotinil
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains: Loteprednol Etabonate 0.5% and Tobramycin 0.3%
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, suspension, White to off white, free from visible contamination
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lotinil (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical<br />anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular<br />conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection<br />or a risk of bacterial ocular infection exists.<br />Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva,<br />cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial<br />punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in<br />certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.<br />They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or<br />thermal burns, or penetration of foreign bodies.<br />The use of a combination drug with an anti-infective component is indicated where the risk of<br />superficial ocular infection is high or where there is an expectation that potentially dangerous<br />numbers of bacteria will be present in the eye.<br />The particular anti-infective drug in this product (tobramycin) is active against the following<br />common bacterial eye pathogens:<br />Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative),<br />including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic<br />species, some nonhemolytic species, and some Streptococcus pneumoniae, Pseudomonas<br />aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis,<br />Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, and H. aegyptius,<br />Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Apply one or two drops of Lotinil into the conjunctival sac of the affected eye every four to six hours.<br />During the initial 24 to 48 hours, the dosing may be increased, to every one to two hours. Frequency should<br />be decreased gradually as warranted by improvement in clinical signs. Care should be taken not to<br />discontinue therapy prematurely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lotinil, as with other steroid anti-infective ophthalmic combination drugs, is contraindicated in most
viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic
keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases
of ocular structures.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intraocular Pressure (IOP) Increase<br />Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in<br />visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma.<br />If this product is used for 10 days or longer, intraocular pressure should be monitored.<br />Cataracts<br />Use of corticosteroids may result in posterior subcapsular cataract formation.<br />Delayed Healing<br />The use of steroids after cataract surgery may delay healing and increase the incidence of bleb<br />formation. In those diseases causing thinning of the cornea or sclera, perforations have been known<br />to occur with the use of topical steroids. The initial prescription and renewal of the medication order<br />should be made by a physician only after examination of the patient with the aid of magnification<br />such as a slit lamp biomicroscopy and, where appropriate, fluorescein staining.<br />Bacterial Infections<br />Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of<br />secondary ocular infections. In acute purulent conditions of the eye, steroids may mask infection or<br />enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be<br />re-evaluated.<br />Viral Infections<br />Employment of a corticosteroid medication in the treatment of patients with a history of herpes<br />simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate<br />the severity of many viral infections of the eye (including herpes simplex).<br />Fungal Infections<br />Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local<br />steroid application. Fungus invasion must be considered in any persistent corneal ulceration where<br />a steroid has been used or is in use. Fungal cultures should be taken when appropriate.<br />Aminoglycoside Hypersensitivity</p><p>Sensitivity to topically applied aminoglycosides may occur in some patients. If hypersensitivity<br />develops with this product, discontinue use and institute appropriate therapy.<br />Risk of Contamination<br />Do not allow the dropper tip to touch any surface, as this may contaminate the suspension.<br />Contact Lens Wear<br />As with all ophthalmic preparations containing benzalkonium chloride, patients should be advised<br />not to wear soft contact lenses when using Loteprednol Etabonate and Tobramycin Ophthalmic<br />Suspension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions have occurred with steroid/anti-infective combination drugs which can be<br />attributed to the steroid component, the anti-infective component, or the combination.<br />In a 42-day safety study comparing Loteprednol Etabonate and Tobramycin Ophthalmic Suspension<br />to placebo, ocular adverse reactions included injection (approximately 20%) and superficial punctate<br />keratitis (approximately 15%). Increased intraocular pressure was reported in 10% (Loteprednol<br />Etabonate and Tobramycin Ophthalmic Suspension) and 4% (placebo) of subjects. Nine percent<br />(9%) of Loteprednol Etabonate and Tobramycin Ophthalmic Suspension subjects reported burning<br />and stinging upon instillation.<br />Ocular reactions reported with an incidence less than 4% include vision disorders, discharge, itching,<br />lacrimation disorder, photophobia, corneal deposits, ocular discomfort, eyelid disorder, and other<br />unspecified eye disorders.<br />The incidence of non-ocular reactions reported in approximately 14% of subjects was headache; all<br />other non-ocular reactions had an incidence of less than 5%.<br />Loteprednol etabonate ophthalmic suspension 0.2% - 0.5%<br />Reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be<br />associated with infrequent optic nerve damage, visual acuity and field defects, posterior subcapsular<br />cataract formation, delayed wound healing and secondary ocular infection from pathogens including<br />herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.<br />In a summation of controlled, randomized studies of individuals treated for 28 days or longer with<br />loteprednol etabonate, the incidence of significant elevation of intraocular pressure (&ge;10 mm Hg)<br />was 2% (15/901) among patients receiving loteprednol etabonate, 7% (11/164) among patients<br />receiving 1% prednisolone acetate and 0.5% (3/583) among patients receiving placebo.</p><p>Tobramycin ophthalmic solution 0.3%<br />The most frequent adverse reactions to topical tobramycin are hypersensitivity and localized ocular<br />toxicity, including lid itching and swelling and conjunctival erythema. These reactions occur in less<br />than 4% of patients. Similar reactions may occur with the topical use of other aminoglycoside<br />antibiotics.<br />Secondary Infection<br />The development of secondary infection has occurred after use of combinations containing steroids<br />and antimicrobials. Fungal infections of the cornea are particularly prone to develop coincidentally<br />with long-term applications of steroids.<br />The possibility of fungal invasion must be considered in any persistent corneal ulceration where<br />steroid treatment has been used.<br />Secondary bacterial ocular infection following suppression of host responses also occurs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Risk Summary<br />There are no adequate and well-controlled studies with loteprednol etabonate or tobramycin in<br />pregnant women.<br />Loteprednol etabonate produced teratogenicity at clinically relevant doses in the rabbit and rat when<br />administered orally during pregnancy. Loteprednol etabonate produced malformations when<br />administered orally to pregnant rabbits at doses &ge; 0.54 times the recommended human ophthalmic<br />dose (RHOD) and to pregnant rats at doses &ge; 13 times the RHOD. In pregnant rats receiving oral<br />doses of loteprednol etabonate during the period equivalent to the last trimester of pregnancy through<br />lactation in humans, survival of offspring was reduced at doses &ge; 1.3 times the RHOD. Maternal<br />toxicity was observed in rats at doses &ge; 135 times the RHOD, and a maternal no observed adverse<br />effect level (NOAEL) was established at 13 times the RHOD.<br />Abortions were observed in pregnant rabbits administered tobramycin via subcutaneous injection at<br />180 times the RHOD. Tobramycin did not affect fetal development when administered by<br />subcutaneous injection to pregnant rats at doses 450 times the RHOD.</p><p>The background risk of major birth defects and miscarriage for the indicated population is unknown.<br />However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and<br />of miscarriage is 15 to 20%, of clinically recognized pregnancies.<br />Data<br />Animal Data<br />Embryofetal studies were conducted in pregnant rabbits administered loteprednol etabonate by oral<br />gavage on gestation days 6 to 18, to target the period of organogenesis. Loteprednol etabonate<br />produced fetal malformations at doses &ge; 0.1 mg/kg/day (0.54 times the recommended human<br />ophthalmic dose (RHOD) based on body surface area, assuming 100% absorption of loteprednol<br />etabonate). Spina bifida (including meningocele) was observed at doses &ge; 0.1 mg/kg/day, and<br />exencephaly and craniofacial malformations were observed at doses &ge; 0.4 mg/kg/day (2.1 times the<br />RHOD). At 3 mg/kg/day (16 times the RHOD), loteprednol etabonate was associated with increased<br />incidences of abnormal left common carotid artery, limb flexures, umbilical hernia, scoliosis, and<br />delayed ossification. Abortion and embryofetal lethality (resorption) occurred at doses &ge; 6<br />mg/kg/day (32 times the RHOD). A NOAEL for developmental toxicity was not established in this<br />study. The NOAEL for maternal toxicity in rabbits was 3 mg/kg/day.<br />Embryofetal studies were conducted in pregnant rats administered loteprednol etabonate by oral<br />gavage on gestation days 6 to 15, to target the period of organogenesis. Loteprednol etabonate<br />produced fetal malformations, including absent innominate artery at doses &ge; 5 mg/kg/day (13 times<br />the RHOD); and cleft palate, agnathia, cardiovascular defects, umbilical hernia, decreased fetal body<br />weight and decreased skeletal ossification at doses &ge; 50 mg/kg/day (135 times the RHOD).<br />Embryofetal lethality (resorption) was observed at 100 mg/kg/day (270 times the RHOD). The<br />NOAEL for developmental toxicity in rats was 0.5 mg/kg/day (1.3 times the RHOD). Loteprednol<br />etabonate was maternally toxic (reduced body weight gain) at doses of &ge; 50 mg/kg/day. The NOAEL<br />for maternal toxicity was 5 mg/kg/day.<br />A peri-/postnatal study was conducted in rats administered loteprednol etabonate by oral gavage<br />from gestation day 15 (start of fetal period) to postnatal day 21 (the end of lactation period). At doses<br />&ge; 0.5 mg/kg/day (1.3 times the RHOD), reduced survival was observed in live-born offspring. Doses<br />&ge; 5 mg/kg/day (13 times the RHOD) caused umbilical hernia/incomplete gastrointestinal tract.<br />Doses &ge; 50 mg/kg/day (135 times the RHOD) produced maternal toxicity (reduced body weight<br />gain, death), decreased number of live-born offspring, decreased birth weight, and delays in<br />postnatal development. A developmental NOAEL was not established in this study. The NOAEL<br />for maternal toxicity was 5 mg/kg/day.</p><p>An embryofetal study was conducted in pregnant rabbits administered 20 or 40 mg/kg/day<br />tobramycin by subcutaneous injection on gestational days 6 to 18, to target the period of<br />organogenesis. Abortions and maternal toxicity (renal nephrosis and cortical tubular necrosis) were<br />observed at both dose levels. The developmental and maternal lowest observed adverse effect level<br />(LOAEL) is 20 mg/kg/day (180 times the RHOD based on body surface area, assuming 100%<br />absorption of tobramycin). An embryofetal study was conducted in pregnant rats administered 50 or<br />100 mg/kg/day tobramycin by subcutaneous injection on gestational days 6 to 15, to target the period<br />of organogenesis. No effects on development, reproduction, or maternal toxicity were reported. The<br />developmental and maternal NOAEL is 100 mg/kg/day (450 times the RHOD).<br />Lactation<br />There are no data on the presence of loteprednol etabonate or tobramycin in human milk, the effects<br />on the breastfed infant, or the effects on milk production. The developmental and health benefits of<br />breastfeeding should be considered, along with the mother&rsquo;s clinical need for Loteprednol Etabonate<br />and Tobramycin Ophthalmic Suspension and any potential adverse effects on the breastfed infant<br />from Loteprednol Etabonate and Tobramycin Ophthalmic Suspension.<br />Pediatric Use<br />Two trials were conducted to evaluate the safety and efficacy of Loteprednol Etabonate and<br />Tobramycin Ophthalmic Suspension (loteprednol etabonate and tobramycin ophthalmic suspension)<br />in pediatric subjects age zero to six years; one was in subjects with lid inflammation and the other<br />was in subjects with blepharoconjunctivitis.<br />In the lid inflammation trial, Loteprednol Etabonate and Tobramycin Ophthalmic Suspension with<br />warm compresses did not demonstrate efficacy compared to vehicle with warm compresses. Patients<br />received warm compress lid treatment plus Loteprednol Etabonate and Tobramycin Ophthalmic<br />Suspension or vehicle for 14 days. The majority of patients in both treatment groups showed reduced<br />lid inflammation.<br />In the blepharoconjunctivitis trial, Loteprednol Etabonate and Tobramycin Ophthalmic Suspension<br />did not demonstrate efficacy compared to vehicle, loteprednol etabonate ophthalmic suspension, or<br />tobramycin ophthalmic solution. There was no difference between treatment groups in mean change<br />from baseline blepharoconjunctivitis score at Day 15.<br />There were no differences in safety assessments between the treatment groups in either trial.<br />Geriatric Use<br />No overall&nbsp;differences in safety and effectiveness have been observed between elderly and younger<br />patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.<br />If there are any transient effects on vision, the patient should be advised to wait until these subside<br />before driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions have occurred with steroid/anti-infective combination drugs which can be<br />attributed to the steroid component, the anti-infective component, or the combination.<br />Loteprednol Etabonate and Tobramycin Ophthalmic Suspension:<br />In a 42-day safety study comparing Loteprednol Etabonate and Tobramycin Ophthalmic Suspension<br />to placebo, ocular adverse reactions included injection (approximately 20%) and superficial punctate<br />keratitis (approximately 15%). Increased intraocular pressure was reported in 10% (Loteprednol<br />Etabonate and Tobramycin Ophthalmic Suspension) and 4% (placebo) of subjects. Nine percent<br />(9%) of Loteprednol Etabonate and Tobramycin Ophthalmic Suspension subjects reported burning<br />and stinging upon instillation.<br />Ocular reactions reported with an incidence less than 4% include vision disorders, discharge, itching,<br />lacrimation disorder, photophobia, corneal deposits, ocular discomfort, eyelid disorder, and other<br />unspecified eye disorders. The incidence of non-ocular reactions reported in approximately 14% of<br />subjects was headache; all other non-ocular reactions had an incidence of less than 5%.<br />Loteprednol etabonate ophthalmic suspension 0.2% - 0.5%<br />Reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be<br />associated with infrequent optic nerve damage, visual acuity and field defects, posterior subcapsular<br />cataract formation, delayed wound healing and secondary ocular infection from pathogens including<br />herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera. In a<br />summation of controlled, randomized studies of individuals treated for 28 days or longer with<br />loteprednol etabonate, the incidence of significant elevation of intraocular pressure (&ge;10 mm Hg)<br />was 2% (15/901) among patients receiving loteprednol etabonate, 7% (11/164) among patients<br />receiving 1% prednisolone acetate and 0.5% (3/583) among patients receiving placebo.<br />Tobramycin ophthalmic solution 0.3%<br />The most frequent adverse reactions to topical tobramycin are hypersensitivity and localized ocular<br />toxicity, including lid itching and swelling and conjunctival erythema. These reactions occur in less<br />than 4% of patients. Similar reactions may occur with the topical use of other aminoglycoside<br />antibiotics.<br />Secondary Infection<br />The development of secondary infection has occurred after use of combinations containing steroids<br />and antimicrobials. Fungal infections of the cornea are particularly prone to develop coincidentally<br />with long-term applications of steroids.</p><p>The possibility of fungal invasion must be considered in any persistent corneal ulceration where<br />steroid treatment has been used.<br />Secondary bacterial ocular infection following suppression of host responses also occurs.<br />To reports any side effect(s):<br />&bull; Saudi Arabia<br />-The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317--2356-2340.<br />Toll free phone: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported. Acute overdosage is unlikely to occur via the ophthalmic<br />route.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay<br />or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration,<br />capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated<br />with inflammation. There is no generally accepted explanation for the mechanism of action of ocular<br />corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase<br />A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the<br />biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by<br />inhibiting the release of their common precursor arachidonic acid.<br />Arachidonic acid is released from membrane phospholipids by phospholipase A2. Corticosteroids<br />are capable of producing a rise in intraocular pressure.<br />Loteprednol etabonate is structurally similar to other corticosteroids. However, the number 20<br />position ketone group is absent.&nbsp;</p><p>The anti-infective component in the combination (tobramycin) is included to provide action against<br />susceptible organisms. In vitro studies have demonstrated that tobramycin is active against<br />susceptible strains of the following microorganisms:<br />Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative),<br />including penicillin-resistant strains.<br />Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species,<br />and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella<br />pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus<br />vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter<br />calcoaceticus and some Neisseria species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a controlled clinical study of ocular penetration, the levels of loteprednol etabonate in the aqueous<br />humor were found to be comparable between Loteprednol Etabonate Ophthalmic Suspension and<br />Loteprednol Etabonate and Tobramycin Ophthalmic Suspension treatment groups.<br />Results from a bioavailability study in normal volunteers established that plasma levels of<br />loteprednol etabonate and &Delta;1 cortienic acid etabonate (PJ 91), its primary, inactive metabolite, were<br />below the limit of quantitation (1 ng/mL) at all sampling times.<br />The results were obtained following the ocular administration of one drop in each eye of 0.5%<br />loteprednol etabonate ophthalmic suspension 8 times daily for 2 days or 4 times daily for 42 days.<br />This study suggests that limited (&lt;1 ng/mL) systemic absorption occurs with 0.5% loteprednol<br />etabonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis<br />Long-term animal studies have not been conducted to evaluate the carcinogenic potential of<br />loteprednol etabonate or tobramycin.<br />Mutagenesis<br />Loteprednol etabonate was not genotoxic in vitro in the Ames test, the mouse lymphoma TK assay,<br />a chromosome aberration test in human lymphocytes, or in an in vivo mouse micronucleus assay.<br />Impairment of Fertility<br />Oral treatment of female and male rats with 25 mg/kg/day of loteprednol etabonate (67 times the<br />RHOD based on body surface area, assuming 100% absorption) prior to and during mating caused<br />preimplantation loss and decreased the number of live fetuses/live births. The NOAEL for fertility<br />in rats was 5 mg/kg/day (13 times the RHOD). Subcutaneous administration of male and female rats&nbsp;with tobramycin did not affect mating behavior or cause impairment of fertility at 100 mg/kg/day<br />(450 times the RHOD based on body surface area, assuming 100% absorption).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benzalkonium Chloride, Glycerol, Tyloxapol, Edetate disodium, Povidone K 90, Sodium Hydroxide<br />1N And / or Sulfuric Acid 5N, Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C. Do not freeze<br />Keep out of the reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary Container: LDPE opaque bottle with LDPE nozzle and HDPE cap.<br />Secondary Container: Carton label and PIL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O. Box 6267, Jeddah 21442
Tel: +966-12-6081111
Fax: +966-12-6081222.
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Feb- 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>